- Home
- NPV vs ACRV Comparison
NPV vs ACRV Comparison
Compare NPV & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPV
- ACRV
- Stock Information
- Founded
- NPV 1993
- ACRV 2018
- Country
- NPV United States
- ACRV United States
- Employees
- NPV N/A
- ACRV N/A
- Industry
- NPV Investment Managers
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- NPV Finance
- ACRV Health Care
- Exchange
- NPV Nasdaq
- ACRV Nasdaq
- Market Cap
- NPV 241.2M
- ACRV 203.9M
- IPO Year
- NPV N/A
- ACRV 2022
- Fundamental
- Price
- NPV $13.17
- ACRV $7.35
- Analyst Decision
- NPV
- ACRV Strong Buy
- Analyst Count
- NPV 0
- ACRV 5
- Target Price
- NPV N/A
- ACRV $22.40
- AVG Volume (30 Days)
- NPV 38.9K
- ACRV 51.7K
- Earning Date
- NPV 01-01-0001
- ACRV 11-13-2024
- Dividend Yield
- NPV 3.90%
- ACRV N/A
- EPS Growth
- NPV N/A
- ACRV N/A
- EPS
- NPV N/A
- ACRV N/A
- Revenue
- NPV N/A
- ACRV N/A
- Revenue This Year
- NPV N/A
- ACRV N/A
- Revenue Next Year
- NPV N/A
- ACRV N/A
- P/E Ratio
- NPV N/A
- ACRV N/A
- Revenue Growth
- NPV N/A
- ACRV N/A
- 52 Week Low
- NPV $8.92
- ACRV $3.19
- 52 Week High
- NPV $11.55
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- NPV 41.83
- ACRV 50.01
- Support Level
- NPV $13.30
- ACRV $6.80
- Resistance Level
- NPV $13.72
- ACRV $7.28
- Average True Range (ATR)
- NPV 0.15
- ACRV 0.45
- MACD
- NPV -0.05
- ACRV 0.06
- Stochastic Oscillator
- NPV 0.00
- ACRV 61.21
About NPV Nuveen Virginia Quality Municipal Income Fund
Nuveen Virginia Quality Municipal Income Fund is a diversified closed-end management investment company. The fund seeks to provide current income exempt from both regular federal and designated state income taxes. The fund invests in a portfolio of municipal obligations issued by state and local government authorities.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.